PEPTIDE

Tirzepatide

Tirzepatide is a first-in-class, long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 39-amino-acid modified synthetic peptide conjugated with a C20 fatty diacid moiety, enabling albumin binding to prolong its half-life for once-weekly dosing, delivering superior glycemic control and weight loss efficacy in metabolic disease research and non-clinical research use.

Tirzepatide is a first-in-class, long-acting dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, a 39-amino-acid modified synthetic peptide with C20 fatty diacid albumin-binding conjugation to extend circulating half-life for once-weekly administration:

Core Mechanism & Key Properties

Selective dual activation of both GIP and GLP-1 receptors delivers complementary, synergistic metabolic effects:
- GLP-1 receptor signaling: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction
- GIP receptor signaling: enhanced insulin sensitivity, improved lipid metabolism, and amplified weight loss efficacy beyond single-target GLP-1 agonists
Albumin-binding modification extends circulating half-life to ~5 days, enabling stable once-weekly dosing
documented in regulatory references for three clinical indications: type 2 diabetes glycemic control, chronic weight management (obesity/overweight with comorbidities), and obstructive sleep apnea in obese patients
Superior glycemic control and weight loss efficacy compared to all single-target GLP-1 receptor agonists in Phase 3 clinical trials

Primary Research Applications

Type 2 diabetes and glycemic regulation research
Obesity and metabolic syndrome weight management studies
Non-alcoholic steatohepatitis (MASH) and cardiovascular disease preclinical and clinical investigations
Heart failure with preserved ejection fraction (HFpEF) research research
Dual incretin receptor signaling mechanism studies

Manufactured to ≥99% purity, sterile-filtered, and lyophilized for long-term stability.

For laboratory research use only; not intended for human or veterinary administration outside of approved clinical protocols.

Research use only: This material is supplied for laboratory research and documentation workflows only. It is not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.

Hytan procurement and documentation support

For Tirzepatide, Hytan Peptides can support research-use sourcing review with available batch COA, vial labeling, product identity notes, storage documentation and wholesale quantity discussion. Product-specific CAS, sequence, molecular weight or method details should be confirmed against the current batch document before procurement decisions.

COA review: request batch-specific purity and identity references where available.
Wholesale planning: confirm vial strength, quantity, lead time, packing and destination requirements.
Compliance: research-use wording should remain clear in quote, invoice and receiving records.

Manufacturing Capability

Controlled production for consistent research peptide supply

Hytan Peptides supports wholesale research peptide orders with organized production workflow, clean handling, standardized filling, labeling and batch-level documentation. From material preparation to final review, each step is managed to support consistent appearance, traceable COA records and dependable supply coordination.

This production overview helps laboratories, distributors and qualified research buyers understand how Hytan Peptides approaches quality-focused peptide manufacturing, packaging and order readiness.